Skip to main content

Table 1 Chronological summary of US Food and Drug Administration approved anti-HER2 treatments in HER2-amplified breast cancer

From: Dual HER2 blockade: preclinical and clinical data

Year of approval

Cancer stage

Agent

Study name

Chemotherapy

1998 [2]

First-line metastatic

T

-

Pac or AC

1998 [2]

Second-line and third-line metastatic

T

-

None

2006 [1],[15]

Adjuvant

T

B31/N9831/BCIG006

AC → Pac, TCH

2006 [16]

Metastatic

L

-

Capecitabine

2009 [17]

Metastatic

L + AI

TAnDEM

None

2012 [18]

Metastatic

P + T

CLEOPATRA

Docetaxel

2013 [13]

Metastatic

TDM-1

EMILIA

None

2013 [19]

Neoadjuvant

P + T

NeoSphere

FEC → Pac, TCH

  1. AI, aromatase inhibitor; AC, doxorubicin and cyclophosphamide; FEC, fluorouracil, epirubicin, cyclophosphamide, HER, human epidermal growth factor receptor; L, lapatinib; P, pertuzumab; Pac, paclitaxel; T, trastuzumab; TCH, docetaxel, carboplatin and trastuzumab; TDM-1, ado-trastuzumab emtansine.